Entasis Therapeutics Holdings Inc. accepted the resignation of Michael Gutch, the Company's Chief Financial Officer and Chief Business Officer, with an effective separation date of February 24, 2022. Effective February 24, 2022, the Company's board of directors has appointed Kristie Wagner on an interim basis as the Company's Vice President, Principal Financial and Accounting Officer. Ms. Wagner, 55, joined the Company in June 2021 as the Company's Vice President, Controller.

Prior to joining Entasis, Ms. Wagner served as vice president and corporate controller at Akebia Therapeutics from November 2013 to May 2021. Before joining Akebia Therapeutics, Ms. Wagner held finance leadership roles at AthenaHealth, Mzinga and GTC Biotherapeutics. Ms. Wagner received her MBA in Finance from Suffolk University and earned a B.S. in Accounting from the Massachusetts College of Liberal Arts.